



## Press Release

Copenhagen, December 26, 2007

**Seventure Partners, one of the most active foreign investors in Scandinavia and the only French shareholder in Danish company Santaris Pharma, is pleased to announce additional financing of €20.4 million (US\$30 million)**

Santaris Pharma, a Danish biopharmaceutical company specializing in the development of RNA antagonists, has announced a financing round of €20.4 million.

This investment was made by an international syndicate of leading venture capital firms specializing in life sciences, headed by Dutch newcomer Gilde Healthcare Partners, providing €7.5 million. The management team and Board members also contributed around €400,000 to the financing round. The remainder was provided by long-standing shareholders, notably Forbion Capital Partners (Netherlands), Global Life Science Venture (Germany), SEVENTURE PARTNERS (France), Omega (Switzerland) and Scandinavian companies BankInvest, Novo Ventures, LD Pensions, Sunstone Capital and InnovationsKapital.

The funds raised will be used primarily for further financing of the development of Santaris Pharma's product portfolio, including RNA antagonist drug candidates based on LNA® (Locked Nucleic Acid).

Following the promising results published in June 2007 for its phase I/II international clinical trial for the treatment of sufferers of chronic lymphoid leukemia (CLL), a cancer of the blood, the company is planning to begin phase II trials with SPC 2996, a Bcl-2 RNA antagonist, in 2008 and initiate a phase I trial for two new RNA antagonists for the treatment of metabolic disorders.



After series C, the company will have cash reserves of over €40 million and more than 85 employees.

Santaris Pharma has a global partnership agreement with US company Enzon Pharmaceuticals for the joint development and marketing of a series of RNA antagonists in oncology.

### About Seventure Partners:

An active partner of companies presenting strong growth potential, Seventure Partners has been investing in innovative sectors since 1997, focusing in particular on French and European companies operating in the ITC and life sciences industries. With some €400 million in assets under management, Seventure Partners stands out as one of Europe's leading VC players. Seventure Partners is a subsidiary of Natixis Private Equity, one of Europe's foremost private equity investors.

In life sciences, our four main investment sectors are biotechnology and pharmaceutical R&D, medical equipment, industrial chemistry and biotechnology and nutrition. However, we also invest in diagnostics, galenic improvements, environmental services, bio-energy, skin care, well-being and services.

For more information about Seventure Partners: [www.seventure.fr](http://www.seventure.fr)

### For more information about Santaris Pharma:

Dr Keith McCullagh, President & CEO, Santaris Pharma A/S, Copenhagen, Denmark. Phone: +45 4517 9819 km@santaris.com	Henrik Stage, Vice-President & CFO, Santaris Pharma A/S, Copenhagen, Denmark. Phone: +45 4517 9888 hs@santaris.com
--	---

### Press contacts:

<b>Seventure</b> Isabelle de Crémoux Member of the Board and Director of the Life Sciences Department Phone: +33 (0)1 58 19 22 77 <a href="mailto:isabelle.decremoux@seventure.fr">isabelle.decremoux@seventure.fr</a>	<b>HDL Communication</b> Delphine Rouget Phone: +33 (0)1 58 65 00 78 <a href="mailto:drouget@hdlcom.com">drouget@hdlcom.com</a>
---	--